WO2019004979A3 - Compositions pharmaceutiques orales solides d'étéxilate de dabigatran - Google Patents

Compositions pharmaceutiques orales solides d'étéxilate de dabigatran Download PDF

Info

Publication number
WO2019004979A3
WO2019004979A3 PCT/TR2018/050220 TR2018050220W WO2019004979A3 WO 2019004979 A3 WO2019004979 A3 WO 2019004979A3 TR 2018050220 W TR2018050220 W TR 2018050220W WO 2019004979 A3 WO2019004979 A3 WO 2019004979A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
solid oral
oral pharmaceutical
dabigatran etexilate
etexilate
Prior art date
Application number
PCT/TR2018/050220
Other languages
English (en)
Other versions
WO2019004979A2 (fr
Inventor
Ezel URAZ
Ali TÜRKYILMAZ
Arzu Palantöken
Yildiz GÜLKOK
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64559741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019004979(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP18811674.3A priority Critical patent/EP3621599A2/fr
Publication of WO2019004979A2 publication Critical patent/WO2019004979A2/fr
Publication of WO2019004979A3 publication Critical patent/WO2019004979A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques orales solides, comprenant de l'étéxilate de dabigatran sous la forme de la base libre ou sous la forme de sels, de polymorphes, de solvates, d'hydrates ou d'esters pharmaceutiquement acceptables de celui-ci.
PCT/TR2018/050220 2017-05-10 2018-05-10 Compositions pharmaceutiques orales solides d'étéxilate de dabigatran WO2019004979A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18811674.3A EP3621599A2 (fr) 2017-05-10 2018-05-10 Compositions pharmaceutiques orales solides d'étéxilate de dabigatran

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/06848A TR201706848A2 (tr) 2017-05-10 2017-05-10 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR2017/06848 2017-05-10

Publications (2)

Publication Number Publication Date
WO2019004979A2 WO2019004979A2 (fr) 2019-01-03
WO2019004979A3 true WO2019004979A3 (fr) 2019-04-11

Family

ID=64559741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050220 WO2019004979A2 (fr) 2017-05-10 2018-05-10 Compositions pharmaceutiques orales solides d'étéxilate de dabigatran

Country Status (8)

Country Link
EP (2) EP3634388A2 (fr)
AU (1) AU2018293361B2 (fr)
BR (1) BR112019023781A2 (fr)
CO (1) CO2019013649A2 (fr)
EA (1) EA201992644A1 (fr)
NZ (1) NZ759901A (fr)
TR (2) TR201706848A2 (fr)
WO (1) WO2019004979A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001156A2 (fr) * 2010-07-01 2012-01-05 Krka, Tovarna Zdravil, D.D., Novo Mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2013124340A1 (fr) * 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN104784147A (zh) * 2014-01-20 2015-07-22 成都苑东药业有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
EP2929884A1 (fr) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2740471B1 (fr) 2012-12-07 2015-05-27 Hexal AG Composition pharmaceutique orale comprenant le dabigatran etexilate
WO2015145462A1 (fr) 2014-03-26 2015-10-01 Cadila Healthcare Limited Compositions pharmaceutiques de dabigatran
IN2015CH01145A (fr) * 2015-03-09 2016-09-16

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001156A2 (fr) * 2010-07-01 2012-01-05 Krka, Tovarna Zdravil, D.D., Novo Mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2013124340A1 (fr) * 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate
CN104784147A (zh) * 2014-01-20 2015-07-22 成都苑东药业有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
EP2929884A1 (fr) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 201675, Derwent World Patents Index; Class A96, AN 2016-637397, XP002789451, BALANAGU H B; BALEBOINA S; BEJAWADA S; CHERUVU R; HILL L A: "Capsule dosage form of direct thrombin inhibitor, useful e.g. for treating deep venous thrombosis and pulmonary embolism, and for reducing risk of stroke and systemic embolism, comprises two types of solid unit dosage forms" *

Also Published As

Publication number Publication date
EA201992644A1 (ru) 2020-04-07
CO2019013649A2 (es) 2020-05-15
TR201806309A2 (tr) 2018-11-21
AU2018293361A1 (en) 2020-01-02
NZ759901A (en) 2021-12-24
TR201706848A2 (tr) 2018-11-21
BR112019023781A2 (pt) 2020-06-02
EP3621599A2 (fr) 2020-03-18
EP3634388A2 (fr) 2020-04-15
WO2019004979A2 (fr) 2019-01-03
AU2018293361B2 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
EP4279071A3 (fr) Nouvelles formulations de cannabinoïdes
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12019501639A1 (en) Jaki selective inhibitors
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
IN2013CH05441A (fr)
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
IN2014MN02245A (fr)
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
WO2016142821A3 (fr) Compositions contenant un inhibiteur de la thrombine
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2016116882A3 (fr) Nouvelles compositions de carfilzomib
WO2019004980A3 (fr) Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
WO2019004979A3 (fr) Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
WO2020032885A3 (fr) Compositions capsule dans capsule d'étéxilate de dabigatran
IN2014MU00859A (fr)
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
TR201722323A2 (tr) Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) Dabi̇gatranin farmasöti̇k kompozi̇syonlari
IN2013MU03421A (fr)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018811674

Country of ref document: EP

Effective date: 20191210

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18811674

Country of ref document: EP

Kind code of ref document: A2